RARE Deadline: RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit Accessibility StatementSkip NavigationNEW YORK, March 25, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.So what: If you purchased Ultragenyx common stock ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ultragenyx (RARE) To Contact Him Directly To Discuss Their Options If you purchased or acquired Ultragenyx common stock between August 3, 2023, to December 26, 2025, and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- What’s Ha ...

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of their Phase III Orbit and Cosmic Studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that the defendants made overly positive statements about setrusumab's efficacy while concealing material adverse facts, leading to inflated stock prices for Ultragenyx [6].

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - The lawsuit claims that Ultragenyx provided misleading information regarding the efficacy of setrusumab in reducing fracture rates in Osteogenesis Imperfecta patients, leading to inflated stock prices [5][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in securities class action settlements since 2013 [4]. Group 3: Case Specifics - The lawsuit alleges that Ultragenyx's positive statements about setrusumab's potential were misleading, as the increase in bone density did not correlate with a decrease in fracture rates, contrary to what was claimed [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of their Phase III Orbit and Cosmic Studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that the defendants made overly positive statements about setrusumab's efficacy while concealing material adverse facts, leading to artificially inflated stock prices for Ultragenyx [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx provided misleading information regarding the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta, claiming confidence in the drug's efficacy while concealing material adverse facts [5][6]. - It is claimed that the positive statements made by the defendants led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor damages when the true information was revealed [6].